Boron delivery agents for neutron capture therapy of cancer.
Boron delivery agents for neutron capture therapy of cancer.
复制标题
DOI：
10.1186/s40880-018-0299-7
复制
发表时间：
2018-06-19
期刊：
影响因子：
--
通讯作者：
Yang W
中科院分区：
文献类型：
--
作者：
Barth RF;Mi P;Yang W
硼中子俘获疗法（英语：Boron neutron capture therapy，BNCT）是一种基于核俘获和裂变反应的二元放射疗法，当稳定同位素硼-10被中子照射产生高能α粒子时发生。这篇综述将集中在肿瘤靶向硼输送剂，这是一个二元系统的重要组成部分。目前临床上使用的两种低分子量含硼药物是硼苯丙氨酸（BPA）和硼癸酸钠（BSH）。虽然它们远不是理想的，但它们的治疗效果已在患有高级别胶质瘤、头颈部复发性肿瘤以及少数皮肤和皮肤外黑色素瘤的患者中得到证实。由于它们的局限性，在过去的40年里，人们花费了大量的努力来开发具有更有利的生物分布和吸收以供临床使用的新的硼递送剂。这些包括含硼卟啉、氨基酸、多胺、核苷、肽、单克隆抗体、脂质体、各种类型的纳米颗粒、硼簇化合物和共聚物。然而，目前这些药物都没有达到有足够令人信服的数据来保证临床生物分布研究的阶段。因此，目前进一步提高BNCT临床疗效的最佳方法是优化BPA和BSH单独或联合给药的给药模式和递送，希望未来的研究将确定新的和更好的硼递送剂用于临床使用。
Boron neutron capture therapy (BNCT) is a binary radiotherapeutic modality based on the nuclear capture and fission reactions that occur when the stable isotope, boron-10, is irradiated with neutrons to produce high energy alpha particles. This review will focus on tumor-targeting boron delivery agents that are an essential component of this binary system. Two low molecular weight boron-containing drugs currently are being used clinically, boronophenylalanine (BPA) and sodium borocaptate (BSH). Although they are far from being ideal, their therapeutic efficacy has been demonstrated in patients with high grade gliomas, recurrent tumors of the head and neck region, and a much smaller number with cutaneous and extra-cutaneous melanomas. Because of their limitations, great effort has been expended over the past 40 years to develop new boron delivery agents that have more favorable biodistribution and uptake for clinical use. These include boron-containing porphyrins, amino acids, polyamines, nucleosides, peptides, monoclonal antibodies, liposomes, nanoparticles of various types, boron cluster compounds and co-polymers. Currently, however, none of these have reached the stage where there is enough convincing data to warrant clinical biodistribution studies. Therefore, at present the best way to further improve the clinical efficacy of BNCT would be to optimize the dosing paradigms and delivery of BPA and BSH, either alone or in combination, with the hope that future research will identify new and better boron delivery agents for clinical use.
登录
查看更多内容
影响因子：
10.8
作者：
Azab, AK;Srebnik, M;Rubinstein, A
通讯作者：
Rubinstein, A
影响因子：
4.7
作者：
Capala, J;Barth, RF;Carlsson, J
通讯作者：
Carlsson, J
影响因子：
7.2
作者：
Daneman, Richard;Prat, Alexandre
通讯作者：
Prat, Alexandre
DOI：
10.1016/j.nano.2013.10.003
发表时间：
2014-04-01
影响因子：
5.4
作者：
Achilli, Cesare;Grandi, Stefania;Minetti, Giampaolo
通讯作者：
Minetti, Giampaolo
DOI：
10.1007/978-3-319-22536-4_16
发表时间：
2016-01-01
期刊：
THERAPEUTIC ULTRASOUND
影响因子：
--
作者：
Burgess, Alison;Hynynen, Kullervo
通讯作者：
Hynynen, Kullervo